Canopy Biosciences
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $2.0m | Seed | |
$2.4m | Series A | ||
N/A | Early VC | ||
N/A | Acquisition | ||
Total Funding | €4.0m |
Related Content
Recent News about Canopy Biosciences
EditCanopy Biosciences, a Bruker company, specializes in providing advanced spatial biology and single-cell analysis tools to biomedical researchers. Founded in 2016 and based in the Cortex Innovation District of St. Louis, Missouri, Canopy Biosciences has rapidly brought innovative technologies from leading academic institutions to market. The company offers a range of products and services, including the CellScape automated imaging platform and NanoString nCounter services, which allow researchers to analyze the expression of up to 800 genes. Canopy Biosciences serves the biomedical research community, focusing on areas such as immuno-oncology, biomarkers, and digital spatial profiling. The company operates on a B2B (business-to-business) model, generating revenue through the sale of its instruments, services, and software solutions. By licensing groundbreaking technologies and making them accessible to researchers worldwide, Canopy Biosciences empowers scientific discovery and innovation.
Keywords: spatial biology, single-cell analysis, biomedical research, CellScape, NanoString nCounter, immuno-oncology, biomarkers, digital spatial profiling, high-plex, multi-omic tools.